| Previous Close | 33.10 |
| Open | 33.09 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 32.83 - 33.10 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 15,723,616 |
| Avg. Volume | 20,276,650 |
| Market Cap | 196.28B |
| Beta | 1.07 |
| PE Ratio (TTM) | 27.69 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.87%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Bloomberg•2 hours ago
AstraZeneca Plunges After Setback in Crucial Lung-Cancer Drug Trial
AstraZeneca Plc shares plunged after the U.K. drugmaker suffered a blow to its next-generation cancer therapy, with a new drug combination failing to do better than chemotherapy in checking the growth ...
- Market Realist•17 hours ago
Understanding Pfizer’s Sterile Injection Pharmaceuticals Position in 2017
In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.
- Zacks•18 hours ago
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.
